AcelRx Pharmaceuticals Inc
NASDAQ:ACRX
AcelRx Pharmaceuticals Inc
NASDAQ:ACRX
Price:
1.1277 USD
2.52%
Market Closed
Updated:
May 4, 2024
AcelRx Pharmaceuticals Inc
Cash from Operating Activities
|
AcelRx Pharmaceuticals Inc
Cash from Operating Activities Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
AcelRx Pharmaceuticals Inc
NASDAQ:ACRX
|
Cash from Operating Activities
-$19m
|
CAGR 3-Years
26%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Operating Activities
$22.8B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Operating Activities
$13.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
17%
|
CAGR 10-Years
12%
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Operating Activities
$8.7B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-7%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Operating Activities
$13B
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
1%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Operating Activities
$4.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-3%
|
See Also
What is AcelRx Pharmaceuticals Inc's Cash from Operating Activities?
Cash from Operating Activities
-19m
USD
-19m
USD
Based on the financial report for Sep 30, 2023, AcelRx Pharmaceuticals Inc's Cash from Operating Activities amounts to -19m USD.
What is AcelRx Pharmaceuticals Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
5%
5%
Over the last year, the Cash from Operating Activities growth was 39%. The average annual Cash from Operating Activities growth rates for AcelRx Pharmaceuticals Inc have been 26% over the past three years , 7% over the past five years , and 5% over the past ten years .
You don't have any saved screeners yet
